Cytek Investor Presentation Deck
1.
Cytek is Becoming the Premier Cell Analysis Company
||||||
like some
8
8+8
Novel, patented FSP platform utilizes the full spectrum of fluorescent signatures
to deliver high-resolution, high-content and high-sensitivity cell analysis
Highly intuitive, integrated workflow solutions driving strong adoption with
over 850 instruments placed since commercial launch in 2017
Validated platform with over 270 peer-reviewed publications, which
continues to accelerate alongside growing applications
Delivering strong revenue growth of 59% YoY for the second quarter of
2021
Potential utility across a myriad of research and clinical applications
could allow Cytek to access the broader $23Bn cell analysis market¹
Comprehensive suite of solutions expands customer base and
diversification, and provides recurring revenue opportunity
2024 market projection estimate
CYTEK
TRANSCEND THE CONVENTIONALView entire presentation